Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neuronetics Inc (STIM)

Neuronetics Inc (STIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,374
  • Shares Outstanding, K 18,729
  • Annual Sales, $ 62,660 K
  • Annual Income, $ -29,040 K
  • 60-Month Beta 1.71
  • Price/Sales 0.81
  • Price/Cash Flow N/A
  • Price/Book 1.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.33
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.36
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.80 +70.00%
on 07/10/20
3.64 -15.93%
on 07/15/20
+1.23 (+67.21%)
since 07/02/20
3-Month
1.70 +80.00%
on 06/22/20
3.64 -15.93%
on 07/15/20
+0.79 (+34.80%)
since 05/05/20
52-Week
1.25 +144.80%
on 03/18/20
12.20 -74.92%
on 09/09/19
-7.31 (-70.49%)
since 08/05/19

Most Recent Stories

More News
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

STIM : 3.01 (+1.00%)
CereVasc Expands Executive Management Team to Advance eShunt(TM) System Development

CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the addition of DJ Cass as Senior Vice President of Business Development & Strategy and Janelle...

STIM : 3.01 (+1.00%)
Neuronetics: 2Q Earnings Snapshot

MALVERN, Pa. (AP) _ Neuronetics Inc. (STIM) on Tuesday reported a loss of $7.8 million in its second quarter.

STIM : 3.01 (+1.00%)
Neuronetics Reports Second Quarter 2020 Financial and Operating Results

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 3.01 (+1.00%)
Neuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 3.01 (+1.00%)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that, in connection with the...

STIM : 3.01 (+1.00%)
Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session

Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

VRAY : 3.47 (+7.43%)
STIM : 3.01 (+1.00%)
Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that Keith J. Sullivan has been...

STIM : 3.01 (+1.00%)
Neuronetics Announces Appointment of Bruce J. Shook to its Board of Directors

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

ANIK : 33.96 (+2.47%)
STIM : 3.01 (+1.00%)
Neuronetics to Present at the William Blair 40th Annual Growth Stock Conference

Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 3.01 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade STIM with:

Business Summary

Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics,...

See More

Key Turning Points

2nd Resistance Point 3.46
1st Resistance Point 3.23
Last Price 3.01
1st Support Level 2.82
2nd Support Level 2.64

See More

52-Week High 12.20
Fibonacci 61.8% 8.02
Fibonacci 50% 6.72
Fibonacci 38.2% 5.43
Last Price 3.01
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar